MedPath
FDA Approval

BRIUMVI

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
TG Therapeutics, Inc.
DUNS: 117372682
Effective Date
January 19, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ublituximab(150 mg in 6 mL)

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Samsung Biologics Co., Ltd.

TG Therapeutics, Inc.

557810567

Packaging Coordinators, LLC

TG Therapeutics, Inc.

078525133

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

BRIUMVI

Product Details

NDC Product Code
73150-150
Application Number
BLA761238
Marketing Category
BLA (C73585)
Route of Administration
INTRAVENOUS
Effective Date
January 19, 2023
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
SODIUM CITRATEInactive
Code: 1Q73Q2JULRClass: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
Code: U59UGK3IPCClass: ACTIBQuantity: 150 mg in 6 mL
© Copyright 2025. All Rights Reserved by MedPath